Genomma Lab InternacionalB de CV (MEX:LABB) Net Change in Cash : MXN1,015 Mil (TTM As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Genomma Lab InternacionalB de CV Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Genomma Lab InternacionalB de CV's Net Change in Cash for the three months ended in Mar. 2025 was MXN-222 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was MXN1,015 Mil.

Genomma Lab InternacionalB de CV Net Change in Cash Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Net Change in Cash Chart

Genomma Lab InternacionalB de CV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

1,180.93

-839.04

33.11

190.39

801.53

Genomma Lab InternacionalB de CV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															-529.44	91.23	595.77	549.98	-222.09

Genomma Lab InternacionalB de CV Net Change in Cash Calculation

Genomma Lab InternacionalB de CV's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	3033.717	+	-731.97	+	-1591.041	+	90.82
	=	802

Genomma Lab InternacionalB de CV's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -151.017 + -89.306 + 32.483 + -14.247

= -222

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,015 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomma Lab InternacionalB de CV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (MEX:LABB) » Definitions » Net Change in Cash

Comparable Companies

ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904 BOM:532321

Traded in Other Exchanges

GNMLF:USA GEKA:Germany

Address

Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210

Website

https://www.genommalab.com

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Genomma Lab InternacionalB de CV Headlines

No Headlines